Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Risk of Hospitalization for Covid-19 Outpatients Treated with Various Drug Regimens in Brazil: Comparative Analysis

Szente Fonseca et al., Travel Medicine and Infectious Disease, doi:10.1016/j.tmaid.2020.101906
Oct 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Hospitalization 64% primary Improvement Relative Risk Hospitalization (b) 51% HCQ  Szente Fonseca et al.  EARLY TREATMENT Is early treatment with HCQ beneficial for COVID-19? Retrospective 717 patients in Brazil Lower hospitalization with HCQ (p=0.00081) c19hcq.org Szente Fonseca et al., Travel Medicine.., Oct 2020 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19hcq.org
64% lower hospitalization with HCQ. Retrospective 717 patients in Brazil with early treatment, adjusted OR 0.32, p=0.00081, for HCQ versus no medication, and OR 0.45, p=0.0065, for HCQ vs. anything else.
Study covers ivermectin and HCQ.
risk of hospitalization, 64.0% lower, RR 0.36, p < 0.001, treatment 25 of 175 (14.3%), control 89 of 542 (16.4%), adjusted per study, odds ratio converted to relative risk, HCQ vs. nothing, primary outcome.
risk of hospitalization, 50.5% lower, RR 0.49, p = 0.006, treatment 25 of 175 (14.3%), control 89 of 542 (16.4%), adjusted per study, odds ratio converted to relative risk, HCQ vs. anything else.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Szente Fonseca et al., 31 Oct 2020, retrospective, Brazil, peer-reviewed, mean age 50.6, 10 authors, average treatment delay 4.6 days, dosage 400mg bid day 1, 400mg qd days 2-5.
This PaperHCQAll
Risk of hospitalization for Covid-19 outpatients treated with various drug regimens in Brazil: Comparative analysis
Silvia Nunes Szente Fonseca, Anastasio De Queiroz Sousa, Alexandre Giandoni Wolkoff, Marcelo Sampaio Moreira, Bruno Castro Pinto, Christianne Fernandes Valente Takeda, Eduardo Rebouças, Ana Paula Vasconcellos Abdon, Anderson L A Nascimento, Harvey A Risch
Travel Medicine and Infectious Disease, doi:10.1016/j.tmaid.2020.101906
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Conflict of Interest Policy Declarations Travel Medicine and Infectious Disease requires that all authors sign a declaration of conflicting interests. If you have nothing to declare in any of these categories then this should be stated. Conflict of Interest A conflicting interest exists when professional judgement concerning a primary interest (such as patient's welfare or the validity of research) may be influenced by a secondary interest (such as financial gain or personal rivalry). It may arise for the authors when they have financial interest that may influence their interpretation of their results or those of others. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Please state any competing interests Funding Source All sources of funding should also be acknowledged and you should declare any involvement of study sponsors in the study design; collection, analysis and interpretation of data; the writing of the manuscript; the decision to submit the manuscript for publication. If the study sponsors had no such involvement, this should be stated. Please state any sources of funding for your research Conflict of Interest A conflicting interest exists when professional judgement concerning a primary interest (such as patient's welfare or the validity of research) may be influenced by a secondary interest (such as financial..
References
Baden, Rubin, Covid-19 -The search for effective therapy, N Engl J Med
Barbosa Esper, Da Silva, Costa Oikawa, Castro, Razuk-Filho et al., Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed-up by telemedicine
Barnett-Howell, Mobarak, The Benefits and Costs of Social Distancing in Rich and Poor Countries
Bialek, Boundy, Bowen, Chow, Cohn et al., Severe outcomes among patients with coronavirus disease 2019 (COVID-19) -United States, February 12, MMWR Morb Mortal Wkly Rep
Brasil, Ministério da Saúde
Brasil, Nota Informativa N o 5/2020-DAF/SCTIE/MS. NOTA INFORMATIVA
Brasil, Perfil Epidemiologico Dos Pacientes Hospitalizados por Sindrome Respiratória Aguda Grave (SRAG)
Cdc, Interim Infection Prevention and Control Recommendations for Patients with Suspected or Confirmed Coronavirus Disease
Durcan, Petri, Immunomodulators in SLE: Clinical evidence and immunologic actions, J Autoimmun
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949
Ge, Wang, Yuan, Xiao, Wang et al., The epidemiology and clinical information about COVID-19, Eur J Clin Microbiol Infect Dis
Grein, Ohmagari, Shin, Diaz, Asperges et al., Compassionate Use of Remdesivir for Patients with Severe Covid-19, N Engl J Med
Guan, Ni, Hu, Liang, Ou et al., Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med
Ip, Ahn, Zhou, Goy, Hansen et al., Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study, Preprints, doi:10.1101/2020.08.20.20178772
J O U R N A L P R E, -p r o o f
Kolilekas, Loverdos, Giannakaki, Vlassi, Levounets et al., Can steroids reverse the severe COVID-19 induced 'cytokine storm'?, J Med Virol, doi:10.1002/jmv.26165
Kucirka, Lauer, Laeyendecker, Boon, Lessler, Variation in False Negative Rate of RT-PCR Based SARS-CoV-2 Tests by Time Since Exposure, Ann Int Med, doi:10.7326/M20-1495
Lagier, Million, Gautret, Colson, Cortaredona et al., Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis, Travel Med Infect Dis
Ly, Zanini, Laforge, Arlotto, Gentile et al., Pattern of SARS-CoV-2 infection among dependant elderly residents living in retirement homes in Marseille, France, Preprints
Nicola, Alsafi, Sohrabi, Kerwan, Al-Jabir et al., The socioeconomic implications of the coronavirus pandemic (COVID-19): A review, Int J Surg
Park, Decloedt, Rayner, Cotton, Mills, Clinical trials of disease stages in COVID 19: complicated and often misinterpreted, Lancet Glob Health, doi:10.1016/S2214-109X(20)30365-X
Rentsch, Devito, Mackenna, Morton, Bhaskaran et al., Hydroxychloroquine for prevention of COVID-19 mortality: a population-based cohort study, Preprints, doi:10.1101/2020.09.04.20187781
Risch, Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis, Am J Epidemiol, doi:10.1093/aje/kwaa093JournalPre-proof
Sanders, Monogue, Jodlowski, Cutrell, Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review, JAMA
Siddiqi, Mehra, COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal, J Heart Lung Transplant
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Who, Who, /Europe | Coronavirus disease (COVID-19) outbreak -WHO announces COVID-19 outbreak a pandemic
Wu, Chen, Cai, Xia, Zhou et al., Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China, JAMA Intern Med, doi:10.1001/jamainternmed.2020.0994
Wu, Mcgoogan, Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention, JAMA
Yao, Ye, Zhang, Cui, Huang et al., In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin Infect Dis, doi:10.1093/cid/ciaa237
{ 'indexed': {'date-parts': [[2024, 2, 14]], 'date-time': '2024-02-14T03:21:56Z', 'timestamp': 1707880916807}, 'reference-count': 36, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2020, 11, 1]], 'date-time': '2020-11-01T00:00:00Z', 'timestamp': 1604188800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}], 'content-domain': { 'domain': [ 'clinicalkey.jp', 'clinicalkey.com', 'clinicalkey.es', 'clinicalkey.fr', 'clinicalkey.com.au', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2020, 11]]}, 'DOI': '10.1016/j.tmaid.2020.101906', 'type': 'journal-article', 'created': { 'date-parts': [[2020, 10, 31]], 'date-time': '2020-10-31T07:44:00Z', 'timestamp': 1604130240000}, 'page': '101906', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 28, 'title': 'Risk of hospitalization for Covid-19 outpatients treated with various drug regimens in Brazil: ' 'Comparative analysis', 'prefix': '10.1016', 'volume': '38', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-2360-7230', 'authenticated-orcid': False, 'given': 'Silvia Nunes', 'family': 'Szente Fonseca', 'sequence': 'first', 'affiliation': []}, { 'given': 'Anastasio', 'family': 'de Queiroz Sousa', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-4347-8621', 'authenticated-orcid': False, 'given': 'Alexandre Giandoni', 'family': 'Wolkoff', 'sequence': 'additional', 'affiliation': []}, {'given': 'Marcelo Sampaio', 'family': 'Moreira', 'sequence': 'additional', 'affiliation': []}, {'given': 'Bruno Castro', 'family': 'Pinto', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Christianne Fernandes', 'family': 'Valente Takeda', 'sequence': 'additional', 'affiliation': []}, {'given': 'Eduardo', 'family': 'Rebouças', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Ana Paula', 'family': 'Vasconcellos Abdon', 'sequence': 'additional', 'affiliation': []}, {'given': 'Anderson L.A.', 'family': 'Nascimento', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-5337-3941', 'authenticated-orcid': False, 'given': 'Harvey A.', 'family': 'Risch', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ {'key': '10.1016/j.tmaid.2020.101906_bib1', 'author': 'Who'}, {'key': '10.1016/j.tmaid.2020.101906_bib2', 'author': 'Cdc'}, { 'key': '10.1016/j.tmaid.2020.101906_bib3', 'doi-asserted-by': 'crossref', 'first-page': '1011', 'DOI': '10.1007/s10096-020-03874-z', 'article-title': 'The epidemiology and clinical information about COVID-19', 'volume': '39', 'author': 'Ge', 'year': '2020', 'journal-title': 'Eur J Clin Microbiol Infect Dis'}, { 'issue': '18', 'key': '10.1016/j.tmaid.2020.101906_bib4', 'doi-asserted-by': 'crossref', 'first-page': '1708', 'DOI': '10.1056/NEJMoa2002032', 'article-title': 'Clinical characteristics of coronavirus disease 2019 in China', 'volume': '382', 'author': 'Guan', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.tmaid.2020.101906_bib5', 'doi-asserted-by': 'crossref', 'first-page': '343', 'DOI': '10.15585/mmwr.mm6912e2', 'article-title': 'Severe outcomes among patients with coronavirus disease 2019 (COVID-19) ' '- United States, February 12-March 16, 2020', 'volume': '69', 'author': 'Bialek', 'year': '2020', 'journal-title': 'MMWR Morb Mortal Wkly Rep'}, { 'key': '10.1016/j.tmaid.2020.101906_bib6', 'doi-asserted-by': 'crossref', 'first-page': '1239', 'DOI': '10.1001/jama.2020.2648', 'article-title': 'Characteristics of and important lessons from the coronavirus disease ' '2019 (COVID-19) outbreak in China: summary of a report of 72314 cases ' 'from the Chinese center for disease control and prevention', 'volume': '323', 'author': 'Wu', 'year': '2020', 'journal-title': 'J Am Med Assoc'}, { 'key': '10.1016/j.tmaid.2020.101906_bib7', 'doi-asserted-by': 'crossref', 'first-page': '934', 'DOI': '10.1001/jamainternmed.2020.0994', 'article-title': 'Risk factors associated with acute respiratory distress syndrome and ' 'death in patients with coronavirus disease 2019 pneumonia in wuhan, ' 'China', 'volume': '180', 'author': 'Wu', 'year': '2020', 'journal-title': 'JAMA Intern Med'}, { 'issue': '1', 'key': '10.1016/j.tmaid.2020.101906_bib8', 'doi-asserted-by': 'crossref', 'first-page': '105949', 'DOI': '10.1016/j.ijantimicag.2020.105949', 'article-title': 'Hydroxychloroquine and azithromycin as a treatment of COVID-19: results ' 'of an open-label non-randomized clinical trial', 'volume': '56', 'author': 'Gautret', 'year': '2020', 'journal-title': 'Int J Antimicrob Agents'}, { 'key': '10.1016/j.tmaid.2020.101906_bib9', 'doi-asserted-by': 'crossref', 'first-page': '2327', 'DOI': '10.1056/NEJMoa2007016', 'article-title': 'Compassionate use of remdesivir for patients with severe covid-19', 'volume': '382', 'author': 'Grein', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.tmaid.2020.101906_bib10', 'doi-asserted-by': 'crossref', 'first-page': '1851', 'DOI': '10.1056/NEJMe2005477', 'article-title': 'Covid-19 - the search for effective therapy', 'volume': '382', 'author': 'Baden', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.tmaid.2020.101906_bib11', 'first-page': '1824', 'article-title': 'Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a ' 'review', 'volume': '323', 'author': 'Sanders', 'year': '2020', 'journal-title': 'J Am Med Assoc'}, { 'key': '10.1016/j.tmaid.2020.101906_bib12', 'article-title': 'ClinicalTrials.gov [internet]. Search of: COVID-19 - list results', 'volume': '15', 'year': '2020', 'journal-title': 'Downloaded June'}, { 'key': '10.1016/j.tmaid.2020.101906_bib13', 'doi-asserted-by': 'crossref', 'first-page': '405', 'DOI': '10.1016/j.healun.2020.03.012', 'article-title': 'COVID-19 illness in native and immunosuppressed states: a ' 'clinical-therapeutic staging proposal', 'volume': '39', 'author': 'Siddiqi', 'year': '2020', 'journal-title': 'J Heart Lung Transplant'}, { 'key': '10.1016/j.tmaid.2020.101906_bib14', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/S2214-109X(20)30365-X', 'article-title': 'Clinical trials of disease stages in COVID 19: complicated and often ' 'misinterpreted', 'author': 'Park', 'year': '2020', 'journal-title': 'Lancet Glob Health'}, {'key': '10.1016/j.tmaid.2020.101906_bib15', 'author': 'Barbosa Esper'}, { 'key': '10.1016/j.tmaid.2020.101906_bib16', 'doi-asserted-by': 'crossref', 'first-page': '101791', 'DOI': '10.1016/j.tmaid.2020.101791', 'article-title': 'Outcomes of 3,737 COVID-19 patients treated with ' 'hydroxychloroquine/azithromycin and other regimens in Marseille, ' 'France: a retrospective analysis', 'author': 'Lagier', 'year': '2020', 'journal-title': 'Trav Med Infect Dis'}, {'key': '10.1016/j.tmaid.2020.101906_bib17', 'author': 'Ly'}, { 'key': '10.1016/j.tmaid.2020.101906_bib18', 'article-title': 'Hydroxychloroquine in the treatment of outpatients with mildly ' 'symptomatic COVID-19: a multi-center observational study', 'volume': '25', 'author': 'Ip', 'year': '2020', 'journal-title': 'Preprints'}, { 'key': '10.1016/j.tmaid.2020.101906_bib19', 'doi-asserted-by': 'crossref', 'first-page': '269', 'DOI': '10.1038/s41422-020-0282-0', 'article-title': 'Remdesivir and chloroquine effectively inhibit the recently emerged ' 'novel coronavirus (2019-nCoV) in vitro', 'volume': '30', 'author': 'Wang', 'year': '2020', 'journal-title': 'Cell Res'}, { 'issue': '15', 'key': '10.1016/j.tmaid.2020.101906_bib20', 'doi-asserted-by': 'crossref', 'first-page': '732', 'DOI': '10.1093/cid/ciaa237', 'article-title': 'In vitro antiviral activity and projection of optimized dosing design ' 'of hydroxychloroquine for the treatment of severe acute respiratory ' 'syndrome coronavirus 2 (SARS-CoV-2)', 'volume': '71', 'author': 'Yao', 'year': '2020', 'journal-title': 'Clin Infect Dis'}, {'key': '10.1016/j.tmaid.2020.101906_bib21', 'author': 'Federal de Medicina'}, {'key': '10.1016/j.tmaid.2020.101906_bib22', 'author': 'Brasil'}, { 'key': '10.1016/j.tmaid.2020.101906_bib23', 'article-title': 'Coronavírus brasil [internet]', 'volume': '15', 'year': '2020', 'journal-title': 'Downloaded June'}, { 'key': '10.1016/j.tmaid.2020.101906_bib24', 'article-title': 'Infogripe- Monitoramento de casos reportados de síndrome respiratória ' 'aguda grave (SRAG) hospitalizados', 'volume': '17', 'year': '2020', 'journal-title': 'Downloaded June'}, { 'key': '10.1016/j.tmaid.2020.101906_bib25', 'first-page': '2020', 'article-title': 'Variation in false negative rate of RT-PCR based SARS-CoV-2 tests by ' 'time since exposure', 'volume': 'August 18', 'author': 'Kucirka', 'year': '2020', 'journal-title': 'Ann Intern Med'}, {'key': '10.1016/j.tmaid.2020.101906_bib26', 'author': 'Barnett-Howell'}, { 'key': '10.1016/j.tmaid.2020.101906_bib27', 'article-title': 'Socio-economic impact of COVID-19', 'volume': '16', 'author': 'United Nations Development Programme', 'year': '2020', 'journal-title': 'Downloaded June'}, { 'key': '10.1016/j.tmaid.2020.101906_bib28', 'doi-asserted-by': 'crossref', 'first-page': '185', 'DOI': '10.1016/j.ijsu.2020.04.018', 'article-title': 'The socio-economic implications of the coronavirus pandemic (COVID-19): ' 'a review', 'volume': '78', 'author': 'Nicola', 'year': '2020', 'journal-title': 'Int J Surg'}, { 'key': '10.1016/j.tmaid.2020.101906_bib29', 'series-title': 'COVID-19 map - johns hopkins coronavirus resource center', 'year': '2020'}, {'key': '10.1016/j.tmaid.2020.101906_bib30', 'author': 'World Health Organization'}, { 'key': '10.1016/j.tmaid.2020.101906_bib31', 'volume': '17', 'year': '2020', 'journal-title': 'Downloaded June'}, { 'key': '10.1016/j.tmaid.2020.101906_bib33', 'first-page': '2020', 'article-title': '184. Notice on issuing the new coronavirus pneumonia diagnosis and ' 'treatment plan (trial version 7)', 'volume': '3', 'year': '2020', 'journal-title': 'Mar'}, { 'key': '10.1016/j.tmaid.2020.101906_bib35', 'doi-asserted-by': 'crossref', 'DOI': '10.1093/aje/kwaa093', 'article-title': 'Early outpatient treatment of symptomatic, high-risk covid-19 patients ' 'that should be ramped-up immediately as key to the pandemic crisis', 'author': 'Risch', 'year': '2020', 'journal-title': 'Am J Epidemiol'}, { 'key': '10.1016/j.tmaid.2020.101906_bib36', 'article-title': 'Hydroxychloroquine for prevention of COVID-19 mortality: a ' 'population-based cohort study', 'volume': '9', 'author': 'Rentsch', 'year': '2020', 'journal-title': 'Preprints September'}, {'key': '10.1016/j.tmaid.2020.101906_bib37', 'author': 'Kolilekas'}, { 'key': '10.1016/j.tmaid.2020.101906_bib38', 'doi-asserted-by': 'crossref', 'first-page': '73', 'DOI': '10.1016/j.jaut.2016.06.010', 'article-title': 'Immunomodulators in SLE: clinical evidence and immunologic actions', 'volume': '74', 'author': 'Durcan', 'year': '2016', 'journal-title': 'J Autoimmun'}], 'container-title': 'Travel Medicine and Infectious Disease', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1477893920304026?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S1477893920304026?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2020, 12, 18]], 'date-time': '2020-12-18T18:29:10Z', 'timestamp': 1608316150000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S1477893920304026'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 11]]}, 'references-count': 36, 'alternative-id': ['S1477893920304026'], 'URL': 'http://dx.doi.org/10.1016/j.tmaid.2020.101906', 'relation': {}, 'ISSN': ['1477-8939'], 'subject': ['Infectious Diseases', 'Public Health, Environmental and Occupational Health'], 'container-title-short': 'Travel Medicine and Infectious Disease', 'published': {'date-parts': [[2020, 11]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Risk of hospitalization for Covid-19 outpatients treated with various drug ' 'regimens in Brazil: Comparative analysis', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'Travel Medicine and Infectious Disease', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.tmaid.2020.101906', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, {'value': '© 2020 Published by Elsevier Ltd.', 'name': 'copyright', 'label': 'Copyright'}], 'article-number': '101906'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit